Analyse BioAge Labs, Inc. (BIOA) — Kairos Score 58/100

À propos de BioAge Labs, Inc.

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Informations clés

🕴️ Activité des initiés (90 jours)

0 transactions — 0 achats et 0 ventes déclarés par les dirigeants de BioAge Labs, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur BIOA dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur BIOA.

• Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
• BioAge Labs' Lead Drug Faces Uncertain Path as Data Looms, UBS Says

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.